Recruiting studies: Alk Gene Rearrangement Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946 Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373 A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016 Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832 Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive La
Phase 1 · 1 location(s) · University of Washington · NCT04231877 Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.